Takeda Farmacêutica Brasil Ltd., the wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has completed the acquisition of Multilab.

The acquisition significantly strengthens Takeda’s existing presence in Brazil, positioning it as one of the top ten pharmaceutical companies in the country. Multilab brings a diverse portfolio of complementary branded generics and OTC products, including Multigrip, the country’s best-selling OTC product for cold and flu treatment in units. OTC products represent approximately 30 per cent of the total Brazilian pharmaceutical market, and the addition of Multigrip will strengthen Takeda’s current OTC portfolio consisting of anti-pain (Neosalodina), digestive support (Eparema), and dermatological (Nebacetin) treatments.

“The acquisition of Multilab demonstrates Takeda’s commitment to Brazil, the world’s sixth largest economy with a pharmaceutical market that has shown consistent growth.” said Giles Platford, president of Takeda Brazil. “The strong distribution network Multilab has established in high growth developing regions of the country, coupled with their portfolio of accessible quality medications, better positions Takeda to meet the diverse healthcare needs of the Brazilian population, in particular the emerging middle class consumer.”

Multilab is a mid-sized pharmaceutical company with annual net revenues of BRL 140 million in 2011. Retail sales for the company grew in excess of +20 per cent p.a. over the period 2009 – 2011. In connection with this acquisition, approximately Japanese Yen 5 billion will be added to the consolidated revenue of Takeda in fiscal 2012.

Takeda is a research-based global company with its main focus on pharmaceuticals. The company is committed to striving toward better health for patients worldwide through leading innovation in medicine.